Article ; Online: Safety and efficacy of tislelizumab plus chemotherapy for first-line treatment of advanced esophageal squamous cell carcinoma and gastric/gastroesophageal junction adenocarcinoma.
2020 Volume 11, Issue 12, Page(s) 3419–3421
MeSH term(s) | Adenocarcinoma/drug therapy ; Adenocarcinoma/pathology ; Antibodies, Monoclonal, Humanized/pharmacology ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antineoplastic Agents, Immunological/pharmacology ; Antineoplastic Agents, Immunological/therapeutic use ; Esophageal Neoplasms/drug therapy ; Esophageal Neoplasms/pathology ; Esophageal Squamous Cell Carcinoma/drug therapy ; Esophageal Squamous Cell Carcinoma/pathology ; Esophagogastric Junction/pathology ; Female ; Humans ; Male ; Stomach Neoplasms/drug therapy ; Stomach Neoplasms/pathology |
---|---|
Chemical Substances | Antibodies, Monoclonal, Humanized ; Antineoplastic Agents, Immunological ; tislelizumab (0KVO411B3N) |
Language | English |
Publishing date | 2020-10-12 |
Publishing country | Singapore |
Document type | Editorial |
ZDB-ID | 2625856-0 |
ISSN | 1759-7714 ; 1759-7706 |
ISSN (online) | 1759-7714 |
ISSN | 1759-7706 |
DOI | 10.1111/1759-7714.13690 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 6921: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.